Bausch Health(BHC)
搜索文档
Bausch Health(BHC) - 2023 Q2 - Earnings Call Presentation
2023-08-03 20:16
Q2 2023 Earnings August 3, 2023 BAUSCH Health Forward-Looking Statements This presentation contains forward-looking information and statements, within the meaning of applicable securities laws (collectively, "forward-looking statements"), including, but not limited to, statements relating to Bausch Health Companies Inc.'s ("Bausch Health" or the "Company") future prospects and performance, financial guidance, proposed plan to separate its eye health business, including the timing thereof, the timing of regu ...
Bausch Health(BHC) - 2023 Q2 - Quarterly Report
2023-08-03 00:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-14956 Bausch Health Companies Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 98-0448205 (State or oth ...
Bausch Health(BHC) - 2023 Q1 - Earnings Call Transcript
2023-05-05 00:24
Bausch Health Companies Inc. (NYSE:BHC) Q1 2023 Earnings Conference Call May 4, 2023 8:00 AM ET Company Participants Thomas Appio - Chief Executive Officer Tom Vadaketh - Chief Financial Officer Mark Maico - Investor Relations Conference Call Participants Glen Santangelo - Jefferies Douglas Miehm - RBC Capital Markets David Amsellem - Piper Sandler Qi Yang - Bank of America Operator Greetings. Welcome to Bausch Health First Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode ...
Bausch Health(BHC) - 2023 Q1 - Quarterly Report
2023-05-04 00:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-14956 Bausch Health Companies Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 98-0448205 (State or ot ...
Bausch Health(BHC) - 2022 Q4 - Earnings Call Presentation
2023-02-23 23:34
| --- | --- | --- | --- | |-------|-------------------|-----------------------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 4Q22 and FY22 | Earnings Presentation | | | | February 23, 2023 | | | Forward-Looking Statements This presentation contains forward-looking information and statements, within the meaning of applicable securities laws (collectively, "forward-looking statements"), including, but not limited to, statements relating to Bausch Health Companies Inc.'s ("Bausch Hea ...
Bausch Health(BHC) - 2022 Q4 - Earnings Call Transcript
2023-02-23 23:32
Bausch Health Companies Inc. (NYSE:BHC) Q4 2022 Earnings Conference Call February 23, 2023 8:00 AM ET Company Participants Thomas Appio - Chief Executive Officer Tom Vadaketh - Chief Financial Officer Conference Call Participants Georgi Yordanov - Cowen and Company Douglas Miehm - RBC Capital Markets Glen Santangelo - Jefferies David Amsellem - Piper Sandler Jason Gerberry - Bank of America Gary Nachman - BMO Umer Raffat - Evercore ISI Operator Good morning, and welcome to Bausch Health's Fourth Quarter 202 ...
Bausch Health(BHC) - 2022 Q4 - Annual Report
2023-02-23 00:00
营收情况 - 公司的营收分别为2022年8124亿美元,2021年8434亿美元和2020年8027亿美元[15] - Salix部门2022年的营收为209亿美元,占总营收的26%;International部门2022年的营收为988亿美元,占总营收的12%;Solta Medical部门2022年的营收为300亿美元,占总营收的4%;Diversified Products部门2022年的营收为978亿美元,占总营收的12%;Bausch + Lomb部门2022年的营收为3768亿美元,占总营收的46%[16] - Salix部门的主要产品Xifaxan®在2022年的营收为1692亿美元,2021年为1644亿美元,2020年为1482亿美元[17] - International部门的主要产品Bisocard®和Thrombo ASS®分别是波兰和俄罗斯的领先品牌[21] - Solta Medical部门的主要产品Next Generation Thermage FLX®在2022年的全球营收为300亿美元[29] - Diversified Products部门的主要产品包括Wellbutrin XL®、Aplenzin®、Cuprimine®、Mysoline®、Ativan®、Xenazine®、Syprine®和Librax®[30][31][32][33][34] - Generics部门的主要产品包括Diastat® AG、Uceris® AG和Elidel® AG[35][36][37] - Ortho Dermatologics部门的主要产品包括Jublia®、Arazlo®、Duobrii®、Siliq®和Targretin®[38][39][40][41] - Dentistry部门的主要产品包括Arestin®和NeutraSal®[43][44] - Bausch + Lomb眼健康业务在2022年、2021年和2020年分别占公司收入的46%、45%和42%[46] - 眼健康业务的主要产品包括PreserVision® AREDS 2、Ocuvite®、Biotrue®、Bausch + Lomb Renu® Advanced Formula等[47][48][49][50] 研发支出 - 研发支出在2022年、2021年和2020年分别为5.29亿美元、4.65亿美元和4.52亿美元,占收入的比例分别约为7%、6%和6%[59][60] 法规和监管 - 公司依靠专利和专有技术保护产品价值,拥有一系列专利覆盖主要产品的关键方面[63] - 政府机构在美国、加拿大、欧盟和其他国家广泛监管制药产品和医疗器械的研发、批准、生产、标签、监测和报告等方面[64] - FDA在美国、加拿大的Health Canada、欧盟的EMA等机构批准新药品或医疗器械的使用前必须获得批准[65] - 美国联邦和州级机构以及其他国家的监管机构对医疗器械、处方药品、OTC药品和化妆品的广告进行监管[66] - 美国联邦反欺诈法规定对向政府提交虚假或欺诈索赔的个人或实体进行民事和刑事责任[67] 风险和挑战 - 公司面临着来自俄乌冲突、COVID-19疫情、B+L分离等因素带来的风险和不确定性,这可能对公司的业务和运营产生重大不利影响[429] - 公司面临的挑战包括新产品、资产和业务的收购和推出,以及对新产品的接受和需求,竞争产品和定价的影响[432] - 公司需要稳定和重新定位其皮肤科业务,以产生额外价值,包括最近推出产品的成功和管道产品的批准[432] - 公司需要竞争对手更大的财务、技术和人力资源,以及其他竞争因素,如竞争对手取得的技术进步、专利和推出的新产品[432]
Bausch Health(BHC) - 2022 Q3 - Earnings Call Presentation
2022-11-03 23:40
Third Quarter 2022 Earnings Call November 3, 2022 Forward-looking statements This presentation contains forward-looking information and statements, within the meaning of applicable securities laws (collectively, "forward-looking statements"), including, but not limited to, statements relating to Bausch Health Companies Inc.'s ("Bausch Health" or the "Company") future prospects and performance, financial guidance, proposed plan to fully separate its eye health business, including the timing thereof, anticipa ...
Bausch Health(BHC) - 2022 Q3 - Earnings Call Transcript
2022-11-03 23:39
Bausch Health Companies Inc. (NYSE:BHC) Q3 2022 Earnings Conference Call November 3, 2022 8:00 AM ET Company Participants Christina Cheng - Senior Vice President, Investor Relations and Communications Thomas Appio - Chief Executive Officer Tom Vadaketh - Chief Financial Officer Conference Call Participants Gary Nachman - BMO Capital Markets Georgi Yordanov - Cowen Umer Raffat - Evercore Greg Fraser - Truist Securities Douglas Miehm - RBC Capital Markets Rishi Parekh - JPMorgan Operator Good morning, ladies ...
Bausch Health(BHC) - 2022 Q2 - Earnings Call Transcript
2022-08-10 00:15
Bausch Health Companies Inc. (NYSE:BHC) Q2 2022 Earnings Conference Call August 9, 2022 8:00 AM ET Company Participants Christina Cheng - Senior Vice President, Investor Relations Thomas Appio - Chief Executive Officer Tom Vadaketh - Chief Financial Officer Conference Call Participants Ken Cacciatore - Cowen & Company Annabel Samimy - Stifel Gary Nachman - BMO Greg Fraser - Truist Securities Umer Raffat - Evercore Sahil Dhingra - RBC Operator Good morning and welcome to the Bausch Health Second Quarter 2022 ...